Tredence acquires life sciences analytics firm KMK Consulting
The acquisition is expected to bring healthcare and life sciences to about 25% of Tredence's revenue by 2028, pairing KMK's two decades of pharma domain expertise with Tredence's AI capabilities.
Takeaways
- KMK Consulting is a analytics and consulting firm for life sciences and biopharma.
- Tredence is acquiring KMK Consulting.
- The target serves healthcare and life sciences across United States.
Tredence has acquired KMK Consulting, a Morris Plains, New Jersey-based analytics and consulting firm focused on life sciences and biopharma, as the AI solutions company aims to derive a quarter of its revenue from healthcare and life sciences by 2028.
Founded in 2000, KMK serves eight of the ten largest global pharmaceutical companies, providing commercial analytics, real-world evidence, and biopharma decision-making support across the product lifecycle.
The deal pairs KMK's deep life sciences domain expertise with Tredence's agentic AI and data engineering capabilities, creating a differentiated offering that spans the pharmaceutical value chain from R&D to commercial launch.
It extends Tredence's reach within the Veeva cloud ecosystem, used by roughly 60-70% of pharma companies worldwide for customer relationship management and sales operations.
Tredence, with 4,200-plus employees globally, specializes in last-mile AI solutions and serves clients across retail, telecom, healthcare, and industrials.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.